ALSENLITE: Senolytics for Alzheimer's Disease (NCT04785300)

🧪 Interventions in This Study

• Dasatinib (DRUG)
• Quercetin (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Mayo Clinic in Rochester — Rochester, Minnesota

📞 Contact the Study Coordinator

Phone: (800) 664-4580

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Mild Cognitive Impairment

• Enhancing Frontal Lobes Plasticity in Mild Cognitive Impairment — Toronto, Ontario
• Remote Game-based Exercise Program for Cognitive and Motor Function Improvement — Los Angeles, California
• Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD) — Boston, Massachusetts
• Glutathione in Mild Cognitive Impairment — Houston, Texas
• Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy — Morgantown, West Virginia
• Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease — Los Angeles, California

Explore by condition: All Mild Cognitive Impairment clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.